Allogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure (Liveradvance)
Therapeutic Effects of Allogenic Mesenchymal Stem Cells in Cirrhotic Patients With Acute-on-chronic Liver Failure. A Double-blind Randomized Placebo-controlled Trial
Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
Terminated
Dificulties to recruit patients and dificulties to obtain MSCs.
Other terminated trials from Clinica Universidad de Navarra, Universidad de Navarra
- Glioblastoma · Phase PHASE1 · Apr 2023
- Asthenia · Phase PHASE3 · Feb 2018
- Old Myocardial Infarction · Phase PHASE2 · Jun 2012
- Cancer · Phase PHASE3 · Dec 2010
- Carcinoma, Small Cell · Phase PHASE2 · Sep 2010
See all terminations from Clinica Universidad de Navarra, Universidad de Navarra
Listed as NCT02857010, this PHASE1 trial focuses on Acute on Chronic Hepatic Failure and remains terminated or withdrawn. Sponsored by Clinica Universidad de Navarra, Universidad de Navarra, it has been updated 7 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Terminated PHASE1
Status: Unknown Status → Terminated
-
Jan 2021 — Mar 2024 [monthly]
Unknown Status PHASE1
-
Mar 2020 — Jan 2021 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Mar 2020 [monthly]
Recruiting PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Clinica Universidad de Navarra, Universidad de Navarra
- Pere Gines
For direct contact, visit the study record on ClinicalTrials.gov .